Literature DB >> 7572919

Multiple ulcerative esophagitis caused by alendronate.

G Maconi1, G Bianchi Porro.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572919

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  13 in total

1.  Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate.

Authors:  P S Kaye
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

2.  52-year-old woman with dysphagia.

Authors:  Sahil Khanna; Amit Noheria; Charles H Rohren
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

Review 3.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 4.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 5.  Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.

Authors:  D Jaspersen
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

6.  Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.

Authors:  L M Lichtenberger; J J Romero; G W Gibson; M A Blank
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

7.  Nonclinical model for assessing gastric effects of bisphosphonates.

Authors:  M A Blank; B L Ems; G W Gibson; W R Myers; S K Berman; R J Phipps; P N Smith
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

Review 8.  Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.

Authors:  Charles H Chesnut
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 9.  A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.

Authors:  J P Devogelaer
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

Review 10.  What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.